UPLC-orbitrap-MS-based metabolic profiling of HaCaT cells exposed to withanolides extracted from Datura metel.L: Insights from an untargeted metabolomics.
Anti-psoriatic mechanism
Cell metabolomics
Datura metel.L
UPLC-orbitrap-MS
Withanolides
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
30 May 2021
30 May 2021
Historique:
received:
13
12
2020
revised:
12
02
2021
accepted:
12
02
2021
pubmed:
13
4
2021
medline:
22
6
2021
entrez:
12
4
2021
Statut:
ppublish
Résumé
In recent decades, more and more attention to the withanolides extracted from Datura metel.L has been paid due to their anti-psoriatic effects. Withanolides have also been reported to exhibit anti-inflammatory and anti-proliferative properties. Thus, withanolides have been considered as a promising candidate of anti-psoriatic drug. The aim of this study was to investigated the metabolic network of HaCaT cells after exposure to withanolides to identify anti-psoriatic mechanism induced by withanolides on skin cells. In this experiment, our results demonstrated that exposure to withanolides at concentrations beyond 50 μg/mL inhibited cell proliferation and induced cell apoptosis in a dose-dependent manner. In addition, withanolides-induced reactive oxygen species (ROS) generation and mitochondrial depolarization in HaCaT cells. In this research, ultra-high performance liquid chromatography coupled with orbitrap mass spectrometry (UPLC-orbitrap-MS) method was applied to profile metabolite changes in HaCaT cells exposed to withanolides. In total, significant variations in 38 differential metabolites were identified between withanolides exposure and untreated groups. The exposure of HaCaT cells to withanolides at the dose of 200 μg/mL for 24 h was revealed by the disturbance of energy metabolism, amino acid metabolism, lipid metabolism and nucleic acid metabolism. UPLC-orbitrap-MS-based cell metabolomics provided a comprehensive method for the identification of withanolides' anti-psoriasis mechanisms in vitro. And above metabolic disorders also reflected potential therapeutic targets for treating psoriasis.
Identifiants
pubmed: 33845385
pii: S0731-7085(21)00091-1
doi: 10.1016/j.jpba.2021.113979
pii:
doi:
Substances chimiques
Withanolides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113979Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors report no declarations of interest.